Exhibit 99.1
Immuron Announces Resignation of Board Member
Melbourne, Australia, October 17, 2019: Immuron Limited (ASX: IMC; NASDAQ: IMRN),an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens,announced today that Mr. Richard Jay Berman has resigned as director of the Company, effective immediately.
“The Board thanks Richard for his varied contributions to Immuron during his time as a director of the company,” said Dr. Gary S. Jacob, CEO of Immuron. “Richard’s broad experience as a board member provided us with a unique and fresh perspective regarding our activities during our many meetings together. I also valued his input during the many conversations he and I had on a variety of topics covering Immuron’s activities. Speaking for all of my colleagues, we wish Richard well in his future endeavors.”
ABOUT IMMURON:
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. Immuron has a novel and safe technology platform with one commercial asset Travelan® generating revenue. Immuron’s lead clinical candidate, IMM-124E, is presently being developed as a drug to prevent Travelers’ Diarrhea. Immuron’s second clinical-stage asset, IMM-529, targetsClostridium difficileInfections (CDI), and is presently in a clinical trial in CDI patients. These products together with the Company’s other preclinical immunotherapy pipeline products currently under development targeting immune-related and infectious diseases are anticipated to meet pressing needs in the global immunotherapy market.
For more information visit: http://www.immuron.com
- - - END - - -
COMPANY CONTACT: Gary S. Jacob, Ph.D. Chief Executive Officer Ph: +61 (0)3 9824 5254 info@immuron.com | AUS INVESTOR RELATIONS: Peter Taylor NWR Communications Ph: +61 (0)4 1203 6231 peter@nwrcommunications.com.au | USA INVESTOR RELATIONS: Dave Gentry - CEO RedChip Companies, Inc. US Ph: +1 (407) 491 4498 dave@redchip.com |
